Video
Vibegron shows efficacy among patients with OAB
Author(s):
“This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well,” says Cornelia Haag-Molkenteller, MD. PhD.
Video Player is loading.
In this video, Cornelia Haag-Molkenteller, MD, PhD, discusses the background and findings of the study, “Once-daily vibegron 75 mg for overactive bladder: Long-term safety and efficacy from a double-blind extension study of the international phase 3 trial (EMPOWUR).” Haag-Molkenteller is a chief medical officer at Urovant Sciences, Inc in Irvine, California.
Related Videos
Hailey Frye discusses improvement of pain management for nephrolithiasis
Ekene Enemchukwu, MD, on trends in vaginal estrogen use for GSM
How rBCG EAP could open up access for Anktiva in bladder cancer
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Anna Myers, CNP, discusses her approach to preventing UTIs
Joshua J. Meeks, MD, PhD, discusses the impact of neoadjuvant durvalumab approval in MIBC
Ian Metzler, MD, on the increasing prevalence of kidney stones in women
How pre-URS tamsulosin use in pediatric patients may reduce repeat procedures
An expert discusses patient counseling in wake of FDA’s labeling changes for testosterone
Related Content
